Malaysia MDA Regulatory Recognition Update 2025: Expanded Reliance Framework And Accelerated Review Pathways

The Medical Device Authority (MDA) of Malaysia has issued a major update to its regulatory recognition and reliance framework, reinforcing the country’s commitment to regulatory efficiency, international harmonization, and accelerated market access for medical devices.

The release of Circular Letter of the MDA Number 2 Year 2025, published on 15 October 2025, introduces important structural revisions, expands the list of recognized regulatory authorities, and updates eligibility conditions for verification assessments.

These changes significantly impact medical device manufacturers pursuing Malaysian market authorization during the 2025–2026 submission cycle.

At Maven Regulatory Solutions, we support global medical device manufacturers with Malaysia MDA registration strategy, ASEAN regulatory reliance pathways, verification assessment preparation, regulatory intelligence monitoring, and accelerated market-entry planning.

Understanding Malaysia’s Regulatory Recognition Framework

Malaysia’s Medical Device Authority has progressively adopted a reliance-based regulatory model designed to reduce duplication of regulatory reviews and accelerate device approvals.

Under this framework, the MDA may recognize:

• Conformity assessments
• Market authorizations
• Regulatory approvals
• Technical evaluations

issued by trusted international regulatory authorities.

Objectives Of the Recognition Framework

The system is intended to:

• Reduce repetitive regulatory assessments
• Accelerate medical device approvals
• Improve regulatory efficiency
• Support faster patient access to innovative technologies
• Enhance ASEAN and global harmonization
• Reduce compliance burdens for manufacturers

Malaysia is increasingly positioning itself as one of the most advanced reliance-driven regulatory systems within the Asia-Pacific region.

1. Background: Evolution of Malaysia’s Recognition & Verification System

Malaysia’s reliance framework has evolved significantly over recent years.

In March 2025, the MDA reissued the foundational regulatory documents governing reliance and verification pathways.

Key Documents Released In 2025

Circular Letter of The MDA Number 1 Year 2025

Accompanied by:

• MDA/GD/0068 – Guidance for Conformity Assessment Bodies conducting verification assessments
• MDA/GD/0070 – Additional implementation guidance

These documents are established:

• Verification assessment procedures
• Eligibility requirements
• Reliance conditions
• Documentation expectations
• Conformity assessment pathways

The verification pathway serves as an alternative to full conformity assessment by leveraging approvals issued by recognized regulatory authorities.

Previously Recognized Authorities Included

• European Union Notified Bodies (EU NB)
• Japan Ministry of Health, Labour and Welfare (MHLW)
• Australia Therapeutic Goods Administration (TGA)
• Health Canada
• U.S. Food and Drug Administration (FDA)
• United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA)

Important Regulatory Principle

• The core objective of the framework is to avoid unnecessary duplication of regulatory review activities.

2. Recognition Framework Explained: Purpose & Regulatory Intent

The updated Circular Letter further clarifies the regulatory intent behind Malaysia’s recognition framework.

Recognition refers to the acceptance of:

• Conformity assessment decisions
• Product approvals
• Regulatory certifications
• Market placement authorizations

from designated trusted regulatory jurisdictions.

Why This Matters

The reliance model helps:

• Reduce administrative complexity
• Improve regulatory predictability
• Accelerate submission review timelines
• Supporting more efficient global product launches
• Facilitate earlier patient access to technologies

The framework also strengthens Malaysia’s participation in international regulatory harmonization initiatives.

3. Expansion Of MDA Reliance Activities In 2025

Malaysia substantially expanded its regulatory reliance initiatives during 2025.

These activities demonstrate the MDA’s long-term strategy toward collaborative international review mechanisms.

3.1 China NMPA Joint Assessments

In January 2025, the MDA formalized collaboration initiatives with China’s National Medical Products Administration (NMPA).

A two-month IVD Regulatory Reliance Program pilot, conducted from:

• 30 July 2025 to 30 September 2025

explored synchronized regulatory review processes and collaborative assessment mechanisms.

Potential Benefits Included

• Faster IVD approvals
• Reduced review duplication
• Enhanced technical collaboration
• Greater regional harmonization
• Improved review efficiency

Strategic Significance

• The NMPA collaboration reflects growing regulatory cooperation between major Asia-Pacific regulatory authorities.

3.2 Singapore HSA Reliance Program

The MDA also launched a second reliance initiative with the Singapore Health Sciences Authority (HSA).

Program Timeline

• Start Date: 1 September 2025
• End Date: 28 February 2026

Eligible medical devices reviewed under the verification pathway may experience substantially reduced review timelines.

Review Timeline Reduction

Important Regulatory Impact

• This represents one of the most significant review-time reductions currently available within ASEAN medical device regulation.

4. The October 2025 Policy Revision: Circular Letter of the MDA Number 2 Year 2025

The updated Circular Letter became effective on:

• 30 September 2025

It was accompanied by the:

• Second Edition of MDA/GD/0068 (September 2025)

The revised guidance introduces several important structural and operational changes.

Key Policy Change: Removal Of the One-Year Market Presence Requirement

One of the most significant revisions involves the removal of the previous condition requiring medical devices to be marketed for at least one year in the recognized authority’s jurisdiction.

Previous Requirement

Manufacturers previously needed to demonstrate:

• At least one year of commercial market presence
• Established regulatory experience in the reference jurisdiction
• Post-market performance evidence

New 2025 Framework

This condition has now been removed.

Why This Is Important

The revision enables:

• Earlier submission opportunities
• Faster reliance eligibility
• Accelerated access to innovative technologies
• Quicker market entry for AI-enabled devices
• Improved pathways for IVD and digital health products

Strategic Impact

• Manufacturers can now leverage newly obtained approvals from recognized authorities without waiting for extended market history.

5. Expansion Of Recognized Countries 

The updated Circular Letter also expands the list of recognized regulatory authorities.

Newly Added Authorities

• Singapore Health Sciences Authority (HSA)
• Thailand Food and Drug Administration (Thai FDA)

Complete Recognized Authority List Now Includes

• EU Notified Bodies
• Japan MHLW
• Australia TGA
• Health Canada
• U.S. FDA
• U.K. MHRA
• Singapore HSA
• Thailand FDA

Why This Expansion Matters

The additions:

• Strengthen ASEAN regulatory harmonization
• Improve regional collaboration
• Expand verification pathway eligibility
• Increase regulatory flexibility
• Improve strategic submission planning

Important Regional Trend

• ASEAN regulators are increasingly adopting reliance-based review models to accelerate innovation and reduce redundant assessment activities.

6. Strategic Implications for Medical Device Manufacturers

Manufacturers planning Malaysian market entry should carefully evaluate the impact of these regulatory updates.

Key Strategic Benefits

Faster Time-To-Market

Expanded eligibility criteria may significantly reduce regulatory review timelines.

Earlier Submission Opportunities

Removal of the one-year market presence requirement supports earlier commercialization strategies.

Broader Reliance Eligibility

Manufacturers with approvals from Singapore HSA or Thailand FDA may now qualify for reliance pathways.

Reduced Administrative Burden

Verification assessments may require less extensive documentation compared to full conformity assessments.

Improved Regulatory Predictability

Reliance frameworks support more efficient global regulatory planning and synchronized market launches.

Greater Support for Emerging Technologies

Digital health, AI-enabled, software-based, and IVD devices may particularly benefit from accelerated pathways.

Comparison: Full Conformity Assessment vs Verification Assessment

7. What Manufacturers Should Do Next

Medical device manufacturers preparing Malaysian submissions during 2025–2026 should consider the following actions.

Recommended Actions

• Review updated Circular Letter requirements
• Assess eligibility for verification pathways
• Align technical documentation with MDA/GD/0068 expectations
• Evaluate ASEAN reliance opportunities
• Monitor reliance pilot program developments
• Update regulatory submission strategies
• Coordinate global and regional launch timelines
• Strengthen regulatory intelligence monitoring

Important Recommendation

• Manufacturers should proactively evaluate reliance eligibility early during regulatory planning to maximize time-to-market advantages.

Impact On Global Medical Device Manufacturers

Manufacturers operating across multiple international markets may experience several operational benefits.

Organizations with strong regulatory intelligence capabilities will be better positioned to leverage these updated pathways.

Future Trends in ASEAN Regulatory Reliance

The MDA’s 2025 updates reflect broader trends across global medical device regulation.

Emerging trends include:

• Increased reliance-based reviews
• Greater ASEAN harmonization
• Collaborative regulatory assessments
• Faster approval pathways for innovative technologies
• Expanded digital health oversight
• Stronger international regulatory cooperation
• Reduced duplication of technical assessments
• More agile regulatory review models

The future Asia-Pacific regulatory environment will likely become increasingly interconnected and reliance-driven.

Quick Facts

• Malaysia MDA updated its reliance framework in October 2025
• Singapore HSA and Thailand FDA are now recognized authorities
• The one-year market presence requirement has been removed
• Verification pathways may reduce review timelines significantly
• Reliance programs with China NMPA and Singapore HSA expanded during 2025
• ASEAN harmonization efforts continue accelerating
• AI-enabled, digital health, and IVD devices may particularly benefit
• Manufacturers should reassess submission strategies for 2025–2026

Why This Matters

Malaysia’s evolving reliance framework creates substantial opportunities for medical device manufacturers seeking faster and more efficient market access.

Organizations that fail to adapt may experience:

• Longer approval timelines
• Missed accelerated review opportunities
• Inefficient regulatory planning
• Increased compliance costs
• Delayed commercialization

Manufacturers that proactively integrate reliance strategies into their global regulatory planning will be better positioned to:

• Accelerate market entry
• Reduce regulatory burden
• Improve launch coordination
• Strengthening ASEAN expansion strategies

How Maven Regulatory Solutions Supports Malaysia MDA Compliance

Our Services

• Malaysia MDA registration strategy
• Verification assessment support
• ASEAN reliance pathway planning
• Technical documentation preparation
• Regulatory intelligence monitoring
• IVD and digital health regulatory support
• Global submission strategy optimization
• Regulatory gap assessments
• Accelerated market-entry consulting
• Post-market compliance support

Why Choose Maven

• Deep expertise in ASEAN medical device regulations
• Strong reliance pathway experience
• Up-to-date regulatory intelligence tracking
• Practical market-entry strategies
• End-to-end submission support
• Experience supporting multinational manufacturers
• Cross-functional regulatory and compliance expertise

Learn more at Maven Regulatory Solutions.

Need Support with Malaysia MDA Regulatory Submissions?

Maven Regulatory Solutions helps medical device manufacturers navigate Malaysia’s evolving reliance framework with confidence.

We Help You With

• Verification pathway eligibility assessments
• Malaysia MDA submission planning
• ASEAN reliance strategy development
• Technical documentation optimization
• Accelerated review preparation
• Regulatory intelligence monitoring
• Digital health and IVD compliance support

Partner With Maven Regulatory Solutions To:

• Accelerate Malaysian market access
• Reduce Regulatory Review Timelines
• Optimize reliance-based submission strategies
• Improve ASEAN regulatory planning
• Reduce compliance burden
• Strengthening global commercialization strategies

Contact Maven Regulatory Solutions today to strengthen your Malaysia MDA regulatory strategy.

Conclusion

Malaysia’s updated recognition and reliance framework reinforces the country’s position as one of the most agile and collaborative medical device regulators within the Asia-Pacific region.

The expansion of recognized authorities, removal of legacy market presence requirements, and continued investment in reliance pilot programs demonstrate the MDA’s commitment to:

• Regulatory modernization
• Faster patient access
• International harmonization
• Efficient review processes
• Innovation-friendly regulation

Manufacturers that proactively adapt to these updated pathways will be better positioned to:

• Accelerate approvals
• Reduce regulatory burden
• Improve commercialization timelines
• Strengthening ASEAN market expansion

Organizations with flexible regulatory strategies and strong reliance-planning capabilities will gain a significant competitive advantage in the evolving Asia-Pacific medical device landscape.

FAQs

1. What is Malaysia’s regulatory reliance framework?

Malaysia’s reliance framework allows the MDA to recognize approvals and conformity assessments issued by trusted international regulatory authorities to accelerate market authorization.

2. Which new authorities were added in 2025?

Singapore HSA and Thailand FDA were added to the recognized authority list.

3. What major eligibility conditions were removed?

The previous requirement for devices to have one year of market presence in the recognized jurisdiction has been removed.

4. How much faster can reliance reviews become?

Certain accelerated reliance pathways may reduce review timelines from 60 working days to 30 working days.

5. Which device categories may benefit most?

AI-enabled devices, digital health technologies, software-based devices, and IVD products may particularly benefit from faster reliance eligibility.

6. What is a verification assessment?

A verification assessment is an alternative regulatory review pathway that relies on approvals from recognized regulatory authorities rather than conducting a full conformity assessment.

7. How can Maven help with Malaysia MDA submissions?

Maven supports verification pathway planning, technical documentation preparation, ASEAN reliance strategy development, and accelerated market-entry support.